MedTrace Logo

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

NCT00867464 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 8670

Last updated 2026-03-03

No results posted yet for this study

Summary

This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.

Conditions

  • Anal Carcinoma
  • Cervical Carcinoma
  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Cervical Carcinoma
  • Oral Cavity Carcinoma

Interventions

OTHER

Cytology Specimen Collection Procedure

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Long-term Follow-up

Undergo extended follow-up

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Aimee Kreimer · National Cancer Institute (NCI)

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-30
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Costa Rica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867464 on ClinicalTrials.gov